Beijing Review: Future-Facing Partnership
BEIJING, May 14, 2025 /PRNewswire/ -- Just as a ship is powered by its sails, people are inspired by their hearts. On November 15, 2024, President Xi Jinping quoted this Latin American proverb in his written speech delivered at the Asia-Pacific Economic Cooperation CEO Summit. He called on all nations to enhance solidarity and cooperation, jointly stand up to global challenges and form a mighty force for the common prosperity of the world and a brighter future for humanity.
Amid shifting international dynamics, the Global South, including China and countries in Latin America and the Caribbean (LAC), is rising with growing strength and influence. China-LAC relations have entered a new phase, setting a new benchmark for South-South cooperation.
In July 2014, during his visit to Brasília, capital of Brazil, Xi attended the China-LAC Countries Leaders' Meeting, where he first proposed building a China-LAC community with a shared future. Together with the attending leaders, he jointly announced the establishment of the Forum of China and Community of Latin American and Caribbean States (CELAC).
In January 2015, the First Ministerial Meeting of the China-CELAC Forum was held in Beijing. This was the beginning of overall cooperation between China and LAC countries. "The China-CELAC Forum, a young seedling in our eyes, needs the dedication and cultivation of both sides for it to grow bigger and stronger," Xi said at the opening ceremony.
Today, that once-tender seedling has grown into a flourishing tree—lush, robust and thriving. From vision to reality, from concept to concrete action, the China-CELAC Forum has become the leading platform for advancing overall cooperation between China and LAC countries.
Over the past decade, the two sides have continuously deepened political mutual trust and expanded practical cooperation. Panama, the Dominican Republic, El Salvador, Nicaragua and Honduras have established or resumed diplomatic ties with China. The latter has firmly held its position as the LAC's second largest trading partner, while Chile, Peru, Costa Rica, Ecuador and Nicaragua have all become China's free trade partners.
In November 2024, the Chancay Port in Peru officially commenced operations. This milestone celebrates the birth of a new land-sea corridor between Asia and LAC countries in the new era.
Over the past decade, China and LAC nations have remained committed to safeguarding world peace and promoting shared development. In May 2024, China and Brazil jointly issued the Common Understandings on Political Settlement of the Ukraine Crisis, which received positive responses from more than 110 countries.
The Fourth Ministerial Meeting of the China-CELAC Forum took place in Beijing on May 13. China has expressed its readiness to work with partners in the region to promote progress in building a China-LAC community with a shared future. Together, they seek to address global challenges, promote reforms in global governance and contribute wisdom and strength to maintaining world peace and stability.
In the spirit of the proverb "just as a ship is powered by its sails, people are inspired by their hearts," the China-LAC community with a shared future is poised for a steady and prosperous voyage, charting a new course for bilateral relations.
Comments to pengjy@cicgamericas.com
TikTokhttps://www.tiktok.com/@cachinachic/video/7503873091957689646?is_from_webapp=1&sender_device=pc&web_id=7227134149436605995
Xhttps://x.com/BeijingReview/status/1922233815889805823
Facebookhttps://www.facebook.com/BJReview/videos/2110423082797950/
YouTubehttps://youtu.be/gm_UYeBAoQ0
Weibohttps://weibo.com/1719349955/5165906364203049
Websitehttp://www.bjreview.com/Multimedia/Video/Wisdom_Without_Borders/202505/t20250514_800401552.html
View original content to download multimedia:https://www.prnewswire.com/news-releases/beijing-review-future-facing-partnership-302456072.html
SOURCE Beijing Review
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
an hour ago
- TechCrunch
After its data was wiped, KiranaPro's co-founder cannot rule out an external hack
Indian grocery delivery startup KiranaPro's recent data loss story has more holes than Swiss cheese, as the startup remains unclear whether the incident was an internal breach or an external hack. Last week, the Bengaluru-based startup discovered that it could not access its back-end servers and that all its data, including its app code, had been deleted from GitHub. The startup on Friday blamed a former employee for the breach. However, in an interview, KiranaPro co-founder and CEO Deepak Ravindran conceded that the company had not deactivated the employee's account after they departed the company and cannot rule out the possibility of subsequent malicious misuse of their account. 'If we go deeper, we have to do a real forensic investigation. We are going to talk [about] this with our board, the investors, and we are going to get a formal opinion on that also with our legal advisers,' Ravindran told TechCrunch. Earlier on Friday, Ravindran claimed in a post on X that the incident that affected its data was an internal breach. 'After careful investigation, we conclude that this was not a hack. No external party penetrated our ordering or payment systems, exploited vulnerabilities, or bypassed security protocols,' he wrote. The co-founder also explicitly shared a screenshot of a LinkedIn profile of one of KiranaPro's former employees on X on Thursday, alleging that they had deleted the startup's code. (TechCrunch is not sharing the post's link, as the startup has yet to offer concrete proof supporting its position.) '[T]his was an internal data breach. Specifically, it was the result of actions taken by a trusted internal employee who had legitimate access to our systems,' the co-founder wrote in his post on Friday. 'This individual intentionally deleted critical server logs while they were being tested and/or edited, an action that goes directly against our policies, our principles, and the trust we place in our team.' When TechCrunch asked if KiranaPro could rule out whether any third party had maliciously gained access to the former employee's account, Ravindran could not. 'We have to do a complete forensic check on the company. We have to do the entire IP scan. We have to look at where the tracks happened. We have to check the computers, MacBooks, and whatever is used. Everything has to be done. Then we have to spend money … so, that's why we decided not to,' he told TechCrunch. Then what was the basis of Ravindran's allegation? It was a GitHub response, a copy of which he shared with TechCrunch. The response included a username, which Ravindran said was associated with the former employee. 'All we have is the emails that we got from GitHub, stating that [the former employee's username] as an individual is the one who deleted the account. We haven't done the investigation further,' Ravindran told TechCrunch. Former employee's account was never offboarded Launched in late 2024, KiranaPro operates as a buyer app on the Indian government's Open Network for Digital Commerce. The startup allows more than 55,000 customers in 50 cities to purchase groceries from their local shops and nearby supermarkets using its voice-based interface. The company also supports local language inputs, including English, Hindi, Malayalam, and Tamil. Ravindran stated that they decided to call out the former employee based on the company's 'belief system,' as they claim the former employee deleted the data after their sudden termination. However, the startup said it is not aware if there were enough protections on the former employee's devices, such as multi-factor authentication, to restrict malicious third-party access, like malware. The company confirmed it did not remove the employee's access to its data and GitHub account following his departure. 'Employee offboarding was not being handled properly because there was no full-time HR,' KiranaPro's chief technology officer, Saurav Kumar, confirmed to TechCrunch. Company restores AWS account and GitHub data Alongside its code saved in GitHub, KiranaPro also lost access to its Amazon Web Services (AWS) account, which included its customer data and their transaction details. Ravindran told TechCrunch that the GitHub data was restored after getting its backup from one of their employees. The startup also regained access to its AWS account along with its customer data. Both the co-founder and CTO said the AWS account was protected by multi-factor authentication, but neither could say how the account was accessed, as nobody else had physical access to Ravindran's phone, which generates the multi-factor code. Nonetheless, Ravindran claimed that the customer data stored in the AWS cloud remained intact and was not accessed by any third parties, nor was it downloaded by the former employee in question. 'Because if that is the case, I will get its notification on email or anything [sic],' he said. That said, Ravindran stated that the startup has enough evidence to file a formal complaint with the police, but said that its investigation is ongoing. The startup has also not fully paid its current employees, the company's co-founder confirmed, soon after the company raised a seed round of ₹100 million Indian rupees (about $1.2 million), which Ravindran said has yet to be fully wired. The startup counts Blume Ventures, Unpopular Ventures, and Turbostart among its institutional venture backers, as well as Olympic medalist PV Sindhu and Boston Consulting Group managing director Vikas Taneja among its angel investors. It has 15 employees located in Bengaluru and Kerala.
Wall Street Journal
an hour ago
- Wall Street Journal
China's Foreign-Exchange Reserves Increased Slightly in May
China's foreign-exchange reserves increased slightly in May, as the Chinese yuan strengthened on a temporary tariff truce with the U.S. and Beijing's recent stimulus measures. The country's foreign-exchange reserves rose $3.6 billion to $3.285 trillion at the end of May, the State Administration of Foreign Exchange said Saturday.
Yahoo
an hour ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
